[High-dose cisplatin in primary non resecable non small cell lung cancer. Results of a multicenter prospective study of 57 cases].
In a prospective multicentre phase II study conducted on 57 patients suffering from carcinologically inoperable non small-cell lung carcinoma, three courses of CDDP 200 mg/m2 were administered at random in 2 dosage regimens: either 100 mg/m2 on Day 1 and Day 8 (arm A), or 40 mg/m2 per day during 5 consecutive days (arm B), every 28 days, with supportive hydration. All 27 patients were assessable for toxicity: there were 10 cases of major intolerance (grade 4 n = 3, grade 3 n = 7) and 34 cases of minor intolerance (grades 1 and 2). Only 27 of the patients who received the 3 planned courses (19 in arm A, 8 in arm B) were assessable for effectiveness which was poor: 10.5% objective response in arm A and 0 response in arm B. Thus, high-dose CDDP administered alone was poorly tolerated and insufficiently effective; intermittent infusions during 5 days did not improve tolerance and were totally ineffective.
Boniface
E
E
Service de Pneumologie, Hôpital de la Croix-Rousse, Lyon.
Guérin
J C
JC
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D002945:Cisplatin
Cisplatine à hautes doses dans les cancers bronchiques non à petites cellules primitifs inopérables. Résultats d'une étude prospective multicentrique sur 57 cas.